Target intelligence / Profile preview

RNA, U2 small nuclear 18, pseudogene (RNU2-18P)

Target
RNU2-18P
Molecular classification
Pseudogene, small nuclear RNA (snRNA), noncoding RNA
01

Overview

RNU2-18P encodes a pseudogene related to the small nuclear RNA U2 family, part of a group of genes derived from functional U2 snRNA sequences. While U2 snRNA is a key RNA component of the spliceosome required for mRNA precursor splicing, pseudogenes like RNU2-18P typically arise from duplication or mutation of functional snRNA genes and do not produce active molecules or functional protein products. RNU2-18P is not known to be involved in any biological regulatory mechanism, disease association, or therapeutic targeting and is not considered a functional gene coding for active snRNA or any other biomolecule. This gene is not considered a therapeutic target, enzyme, transporter, receptor, or member of a druggable family. The "is_incorrect" entry is set to true because pseudogenes such as RNU2-18P are not typically considered biological targets with functional relevance, and no evidence links this gene to disease processes, drugs, biomarkers, or therapeutic safety challenges. No evidence exists that this pseudogene is involved in signal transduction, cell cycle, apoptosis, immune response, or any other canonical biological function. If the functional U2 snRNA is intended, reference should shift to the active U2 snRNA genes (e.g., RNU2-1, RNU2), which participate in splicing as part of the spliceosome. RNU2-18P is best classified as a member of the noncoding RNA pseudogene family associated with the U2 small nuclear RNAs rather than as a separate molecular target or receptor.

Other names
RNU2-18PRNA, U2 small nuclear 18, pseudogene

Beyond the preview

Go deeper on RNA, U2 small nuclear 18, pseudogene (RNU2-18P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U2 small nuclear 18, pseudogene (RNU2-18P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call